I have a friend doing her PhD in cancer research. She tells me to take every Phase I trial with a huge grain of salt, because they rarely make it to market. [1]
There’s a lot of approved cancer treatment protocols that increase median survival by a mere few weeks. This drug also seems to be heading that way.
It's part of the huge, finger in the air balancing act of developing drugs. How much money do you put into early phase 1 and before stuff that may or may not make it. And what's the market if it does make it. Because the ones that do make it have to cover the cost of all the ones that don't, who's learning it took to get to this point.
Is this image from something with stats? The numbers seem kind of round.